Results from the phase 3 MIRASOL study by Tashanna Myers at SGO25
Moffitt Cancer Center shared a post on LinkedIn:
“During the SGO Meeting, Tashanna Myers, MD from Baystate Medical Center presents results from the phase 3 MIRASOL study, which tested the impact of treatment-emergent ocular events on health-related quality of life in patients with FRα-positive platinum-resistance ovarian cancer treated with mirvetuximab soravtansine.
Key findings:
• Occurrence of treatment-emergent ocular events showed no significant association with HRQoL detriments among patients treated with MIRV.
• No statistically significant differences were observed in the EORTC QLQ-C30 subscales (GHS/QoL and PF) and EQ-5D-5L measures between patients with treatment-emergent blurred vision/keratopathy vs patients with no treatment-emergent ocular events at 9, 15, and 21 weeks after treatment initiation.
• A sensitivity analysis that broadened the definition of ocular events from blurred vision/keratopathy to any treatment-emergent ocular events showed no statistically significant differences in select HRQOL PRO measures across time points.
• These findings indicate that MIRV treatment benefit outweighs the impact of treatment-emergent ocular events on HRQoL, supporting MIRV as the new standard of care for patients with FRa-positive PROC.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023